Abstract Body: Introduction: In randomized controlled trials, semaglutide reduces cardiovascular risks in individuals with obesity/overweight without diabetes. However, its real-world impact on cardiometabolic risk factors remains unclear in this group.
Methods: We conducted a multi-center analysis of electronic health records data from Yale New Haven Health (01/2018-12/2022) and Sentara Health (01/2018-06/2023). The study population included adults without diabetes mellitus who were prescribed semaglutide and had regular follow-ups over 24 months. The index date was the date of the first prescription of semaglutide. The percent (%) change in weight from baseline and blood pressure (BP) (mmHg) were fit in separate linear regression models. A random-effects meta-analysis was used to synthesize the results from different sites.
Results: A total of 523 patients without diabetes prescribed semaglutide at Yale and Sentara were included in the analyses. The study population had a mean (SD) age of 56.6 (12.6) years, 69.6% were female, and the mean (SD) BMI was 37.9 (8.4) kg/m². We observed a continuous decrease in body weight over 24 months (Figure 1). At 18-23 months, body weight among these patients was significantly reduced by 4.8 % (2.2, 7.4%). Systolic BP was significantly reduced by 2.03 mmHg (0.4, 3.7 mmHg) at 18-23 months, while there was no significant change in diastolic BP at the end of the study period.
Conclusions: This multi-center analysis provided preliminary results of the impact of semaglutide on body weight and BP in real-world settings in individuals without diabetes. These findings highlight the importance of post-market surveillance of novel anti-obesity medications.